In patients with hypertriglyceridaemia, volanesorsen reduced plasma triglyceride (TG) by 71.2% at 3 months vs 0.9% with placebo (p<0.0001).
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
